These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 27106625)

  • 1. The effects of VEGF-A-inhibitors aflibercept and ranibizumab on the ciliary body and iris of monkeys.
    Ludinsky M; Christner S; Su N; Taubitz T; Tschulakow A; Biesemeier A; Julien-Schraermeyer S; Schraermeyer U
    Graefes Arch Clin Exp Ophthalmol; 2016 Jun; 254(6):1117-25. PubMed ID: 27106625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes.
    Julien S; Biesemeier A; Taubitz T; Schraermeyer U
    Br J Ophthalmol; 2014 Jun; 98(6):813-25. PubMed ID: 24457369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys.
    Tschulakow A; Christner S; Julien S; Ludinsky M; van der Giet M; Schraermeyer U
    PLoS One; 2014; 9(11):e113701. PubMed ID: 25415380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of commonly used intravitreal anti-vascular endothelial growth factor drugs on mesenchymal stem cells derived from the limbus and ciliary body.
    Acar U; Erginturk Acar D; Alpaslan Pinarli F; Demir MN; Beyazyildiz E; Ozdemir O; Gulmez Sevim D; Tiryaki M; Sobaci G
    Clin Exp Ophthalmol; 2016 Sep; 44(7):587-596. PubMed ID: 26856706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
    Schottler J; Randoll N; Lucius R; Caliebe A; Roider J; Klettner A
    Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration.
    Wang X; Sawada T; Sawada O; Saishin Y; Liu P; Ohji M
    Am J Ophthalmol; 2014 Oct; 158(4):738-744.e1. PubMed ID: 24973606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to anti-VEGF-A treatment of retinal pigment epithelial cells in vitro.
    Puddu A; Sanguineti R; Traverso CE; Viviani GL; Nicolò M
    Eur J Ophthalmol; 2016 Aug; 26(5):425-30. PubMed ID: 27079208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranibizumab and Aflibercept: Intraocular Pharmacokinetics and Their Effects on Aqueous VEGF Level in Vitrectomized and Nonvitrectomized Macaque Eyes.
    Niwa Y; Kakinoki M; Sawada T; Wang X; Ohji M
    Invest Ophthalmol Vis Sci; 2015 Oct; 56(11):6501-5. PubMed ID: 26447985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal Aflibercept and Ranibizumab Injections for Polypoidal Choroidal Vasculopathy.
    Cho HJ; Kim KM; Kim HS; Han JI; Kim CG; Lee TG; Kim JW
    Am J Ophthalmol; 2016 May; 165():1-6. PubMed ID: 26921806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PERMEABILITY AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR EFFECTS OF BEVACIZUMAB, RANIBIZUMAB, AND AFLIBERCEPT IN POLARIZED RETINAL PIGMENT EPITHELIAL LAYER IN VITRO.
    Yoshihara N; Terasaki H; Shirasawa M; Kawano H; Sonoda S; Yamaguchi M; Hashiguchi T; Hisatomi T; Ishibashi T; Sakamoto T
    Retina; 2017 Jan; 37(1):179-190. PubMed ID: 28005721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physician-Industry Interactions and Anti-Vascular Endothelial Growth Factor Use Among US Ophthalmologists.
    Taylor SC; Huecker JB; Gordon MO; Vollman DE; Apte RS
    JAMA Ophthalmol; 2016 Aug; 134(8):897-903. PubMed ID: 27356110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.
    Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular Endothelial Growth Factor (VEGF) Concentration Is Underestimated by Enzyme-Linked Immunosorbent Assay in the Presence of Anti-VEGF Drugs.
    Takahashi H; Nomura Y; Nishida J; Fujino Y; Yanagi Y; Kawashima H
    Invest Ophthalmol Vis Sci; 2016 Feb; 57(2):462-6. PubMed ID: 26868748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to anti-VEGF-A treatment of endothelial cells in vitro.
    Puddu A; Sanguineti R; Traverso CE; Viviani GL; Nicolò M
    Exp Eye Res; 2016 May; 146():128-136. PubMed ID: 26771090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage.
    Klettner A; Grotelüschen S; Treumer F; Roider J; Hillenkamp J
    Br J Ophthalmol; 2015 Jun; 99(6):864-9. PubMed ID: 25740806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranibizumab and Bevacizumab but Not Aflibercept Inhibit Proliferation of Primary Human Retinal Pigment Epithelium in vitro.
    Parisi L; Fuhrer R; Zinkernagel M; Enzmann V
    Ophthalmologica; 2019; 241(3):137-142. PubMed ID: 30001546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of mouse VEGF neutralization by ranibizumab and aflibercept.
    Ichiyama Y; Matsumoto R; Obata S; Sawada O; Saishin Y; Kakinoki M; Sawada T; Ohji M
    PLoS One; 2022; 17(12):e0278951. PubMed ID: 36542626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD.
    Batioglu F; Demirel S; Özmert E; Abdullayev A; Bilici S
    BMC Ophthalmol; 2015 Apr; 15():40. PubMed ID: 25885684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.